Institut National De La Sante Et De La Recherche Medicale

Université De Nantes

Chu Nantes

Centre National De La Recherche Scientifique

Other

New York University

Institut Francais De Recherche Pour L'exploitation De La Mer (Ifremer)

Ecole Nationale Veterinaire

The University of Nantes

Inserm

Jérôme Guicheux

Pierre Weiss

Guy Daculsi

Bruno Bujoli

Jean-Michel Bouler

Pascal Janvier

Eva Mathieu

Solen Josse

Patricia Lemarchand

Ibrahim Khairoun

Racquel Z LeGeros

Gildas Rethore

Gaël Grimandi

Emile Rederstorff

Mathilde Mosser

Samia Laib

Apolline Salama

Anne Moure

Claire Vinatier

Xavier Leveque

Jean-Michael Bouler

Cécile Boyer

Olivier Gauthier

David Riochet

Jean-Marie Bach

The present invention relates to the use of insulin-producing cells encapsulated in silanized hydroxypropyl methylcellulose (Si-HPMC) for the treatment of type 1 diabetes. Methods and kits are also provided for restoring and/or maintaining euglycemia in type 1 diabetic patients and in type 1 prediabetic patients.

Si-HPMC-encapsulated insulin-producing cells for the treatment of type 1 diabetes

The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.

Silylated biomolecule-based hydrogel for culturing cardiomyocytes and stem cells, and use of the hydrogel thereof for treating heart failure

The invention concerns: &#x2014;a silylated biomolecule having the following formula (I): &#x2014;the process for the preparation of a silylated biomolecule of formula (I), &#x2014;the use of a silylated biomolecule of formula (I) to functionalize the surface of a support, &#x2014;a process for the preparation of a hydrogel by use of a silylated biomolecule of formula (I), the hydrogel obtainable by said process, &#x2014;said hydrogel as a biological tissue substitute, &#x2014;a composition comprising said hydrogel in a pharmaceutically acceptable vehicle, &#x2014;said composition for the release of active principle. 

Silylated biomolecules

The invention relates to the use of a silanised hydroxypropylmethylcellulose (HPMC) or silanised hydroxyethylcellulose (HEC) hydrogel, self-crosslinking as a function of pH, for the three-dimensional ex vivo culture of chondrocytes.

Use of a hydrogel for the culture of chondrocytes

A phosphocalcic compound modified by a gem-bisphosphonic acid or one of its salts, a method for preparing same, as well as its use for preparing an injectable composition. The modified phosphocalcic compound is obtained by adding a gem-bisphosphonic acid or one of its alkali metal or alkaline earth salts to a suspension of a precursor phosphocalcic compound in ultras-pure water, while stirring the reaction medium at room temperature, then in recovering by centrifuging the formed compound. The compound is useful for making an injectable composition, for use in the treatment of bone remodeling equilibrium.

Modified phosphocalcic compound, injectable composition containing same

The invention concerns a phosphocalcic compound modified by a gem-bisphosphonic acid or one of its salts, a method for preparing same, as well as its use for preparing an injectable composition. The modified phosphocalcic compound is obtained by adding a gem-bisphosphonic acid or one of its alkali metal or alkaline earth salts to a suspension of a precursor phosphocalcic compound in ultra-pure water, while stirring the reaction medium at room temperature, then in recovering by centrifuging the formed compound. Said compound is useful for making an injectable composition, for use in the treatment of bone remodeling equilibrium.

A composition and method for producing interconnective macroporous, resorbable and injectable calcium phosphate-based cements (MICPCs). The composition of the invention sets to poorly crystalline apatitic calcium phosphate after mixing a powder component and an aqueous solution. The multiphasic calcium phosphate components in the cement resorb at different rates allowing the timely replacement by new bone. The interconnected macroporosity in the cement allows for vascularization, entrapment of growth factors, cell colonization and tissue ingrowth. This MICPC can be used for dental and medical applications relating to bone repair, augmentation, reconstruction, regeneration, and osteoporosis treatment, and also for drug delivery, and as scaffolds for tissue engineering.

Macroporous, resorbable and injectible calcium phosphate-based cements (MCPC) for bone repair, augmentation, regeneration, and osteoporosis treatment

Growing community of inventors

Nantes, France

Jérôme Guicheux